Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants
Downloaden 1.04 MBAuteurs
Lucy Catteau [3]; Nicolas Dauby [4]; Marion Montourcy [5]; Bottieau, Emmanuel [6]; Joris Hautekiet [7]; Goetghebeur, Els [8]; Sabrina Van Ierssel [9]; Els Duysburgh [10]; Herman Van Oyen [11]; Chloé Wyndham-Thomas [12]; Dominique Van Beckhoven [13]; Kristof Bafort [14]; Leïla Belkhir [15]; Nathalie Bossuyt [16]; Philippe Caprasse [17]; Vincent Colombie [18]; De Munter, Paul [19]; Jessika Deblonde [20]; Didier Delmarcelle [21]; Mélanie Delvallee [22]; Demeester, Rémy [23]; Thierry Dugernier [24]; Xavier Holemans [25]; Benjamin Kerzmann [26]; Pierre Yves Machurot [27]; Philippe Minette [28]; Jean-Marc Minon [29]; Saphia Mokrane [30]; Catherine Nachtergal [31]; Séverine Noirhomme [32]; Piérard, Denis [33]; Camelia Rossi [34]; Schirvel, Carole [35]; Erica Sermijn [36]; Frank Staelens [37]; Filip Triest [38]; Nina Van Goethem [39]; Jens Van Praet [40]; Anke Vanhoenacker [41]; Roeland Verstraete [42]; Elise Willems [43]Trefwoorden
Samenvatting:
Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19 across various
settings at a total dose usually ranging from 2400 mg to 9600 mg. In Belgium, off-label use of
low-dose HCQ (total 2400 mg over 5 days) was recommended for hospitalised patients with COVID-19.
We conducted a retrospective analysis of in-hospital mortality in the Belgian national COVID-19 hospital
surveillance data. Patients treated either with HCQ monotherapy and supportive care (HCQ group) were
compared with patients treated with supportive care only (no-HCQ group) using a …